Q3 2021 Investor Relations Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations CRM IHD MayzentⓇ - S1P1,5 receptor modulator Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients NCT04926818 NEOS (CBAF312D2301) Multiple sclerosis, pediatrics Phase 3 180 Annualized relapse rate (ARR) in target pediatric participants Arm 1: Experimental ofatumumab - 20 mg injection/ placebo Arm 2: Experimental siponimod - 0.5 mg, 1 mg or 2 mg/ placebo Arm 3: Active Comparator fingolimod - 0.5 mg or 0.25 mg/ placebo Children/adolescent patients aged 10-17 years old with Multiple Sclerosis (MS). he targeted enrollment is 180 participants with multiple sclerosis which will include at least 5 participants with body weight (BW) ?40 kg and at least 5 participants with age 10 to 12 years in each of the ofatumumab and siponimod arms. There is a minimum 6 month follow up period for all participants (core and extension). Total duration of the study could be up to 7 years. Read-out Milesstone(s) Publication 90 Investor Relations | Q3 2021 Results 2026 TBD NOVARTIS | Reimagining Medicine

View entire presentation